AB 1753: Controlled substances: CURES database.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-09-18
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance. Existing law requires prescription forms for controlled substance prescriptions to be obtained from security printers approved by the department, as specified. Existing law requires a dispensing pharmacy, clinic, or other dispenser to report specified information to the department.
This bill would authorize the department to reduce or limit the number of approved printers to 3, as specified. The bill would require prescription forms for controlled substance prescriptions to have a uniquely serialized number, in a manner prescribed by the department, and would require a printer to submit specified information to the department for all prescription forms delivered. The bill would require the information submitted by a dispensing pharmacy, clinic, or other dispenser to the department to include the serial number for the corresponding prescription form, if applicable.
This bill would incorporate additional changes to Section 11165 of the Health and Safety Code proposed by AB 1751 to be operative only if this bill and AB 1751 are enacted and this bill is enacted last.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance. Existing law requires prescription forms for controlled substance prescriptions to be obtained from security printers approved by the department, as specified. Existing law requires a dispensing pharmacy, clinic, or other dispenser to report specified information to the department.
This bill would authorize the department to reduce or limit the number of approved printers to 3, as specified. The bill would require prescription forms for controlled substance prescriptions to have a uniquely serialized number, in a manner prescribed by the department, and would require a printer to submit specified information to the department for all prescription forms delivered. The bill would require the information submitted by a dispensing pharmacy, clinic, or other dispenser to the department to include the serial number for the corresponding prescription form, if applicable.
This bill would incorporate additional changes to Section 11165 of the Health and Safety Code proposed by AB 1751 to be operative only if this bill and AB 1751 are enacted and this bill is enacted last.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance. Existing law requires prescription forms for controlled substance prescriptions to be obtained from security printers approved by the Department of Justice, department, as specified. Existing law requires a dispensing pharmacy, clinic, or other dispenser to report specified information to the Department of Justice. department.
This bill would authorize the Department of Justice department to reduce or limit the number of approved printers to 3, as specified. The bill would require prescription forms for controlled substance prescriptions to have a uniquely serialized number, in a manner prescribed by the Department of Justice, department, and would require a printer to submit specified information to the Department of Justice department for all prescription forms delivered. The bill would require the information submitted by a dispensing pharmacy, clinic, or other dispenser to the Department of Justice department to include the serial number for the corresponding prescription form, if applicable.
This bill would incorporate additional changes to Section 11165 of the Health and Safety Code proposed by AB 1751 to be operative only if this bill and AB 1751 are enacted and this bill is enacted last.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance. Existing law requires prescription forms for controlled substance prescriptions to be obtained from security printers approved by the Department of Justice, as specified. Existing law requires a dispensing pharmacy, clinic, or other dispenser to report specified information to the Department of Justice.
This bill would, beginning January 1, 2020, require would authorize the Department of Justice to reduce or limit the number of approved printers to 3, as specified. The bill would require prescription forms for controlled substance prescriptions to have a uniquely serialized number, in a manner prescribed by the Department of Justice, and would require a printer to submit specified information to the Department of Justice for all prescription forms delivered. The bill would require the information submitted by a dispensing pharmacy, clinic, or other dispenser to the Department of Justice to include the serial number for the corresponding prescription pad, form, if applicable.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance. Existing law requires prescription forms for controlled substance prescriptions to be obtained from security printers approved by the Department of Justice, as specified. Existing law requires a dispensing pharmacy, clinic, or other dispenser to report specified information to the Department of Justice.
This bill would, beginning January 1, 2020, require the Department of Justice to limit the number of approved printers to 3, as specified. The bill would require prescription forms for controlled substance prescriptions to have a uniquely serialized number, in a manner prescribed by the Department of Justice, and would require a printer to submit specified information to the Department of Justice for all prescription forms delivered. The bill would require the information submitted by a dispensing pharmacy, clinic, or other dispenser to the Department of Justice to include the serial number for the corresponding prescription pad, if applicable.
The Legislature finds and declares the following:
(a)The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
(b)Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
(c)Many states have begun to require that all controlled substances be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
(d)Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
SEC. 2.Section 11161.5 of the Health and Safety Code is amended to read:11161.5.(a)Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
(b)The department may approve security printer applications after the applicant has provided the following information:
(1)Name, address, and telephone number of the applicant.
(2)Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
(3)Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
(4)(A)The location, names, and titles of the applicants agent for service of process in this state; all principal corporate officers, if any; all managing general partners, if any; and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms.
(B)A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, managing general partner, or of any person described in subparagraph (A).
(5)(A)A signed statement indicating whether the applicant, any principal corporate officer, any managing general partner, or any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, has ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.
(B)The department shall provide the applicant and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.
(C)Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (l) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
(D)The department shall assess against each security printer applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks and inspections of security printers pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits the security printer application, fingerprints, and related information to the department.
(E)The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
(c)The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
(d)The department may deny a security printer application on any of the following grounds:
(1)The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.
(2)The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
(3)The applicant committed any act that would constitute a violation of this division.
(4)The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
(5)The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
(6)The department determines that the applicant has submitted an incomplete application.
(7)As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
(e)An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
(f)The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
(g)Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances with the federal Drug Enforcement Administration (DEA).
(h)Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by a means that requires a signature signifying receipt of the package and provision of that signature to the security printer. Controlled substance prescription forms provided in person shall be restricted to established customers. Security printers shall obtain a photo identification from the customer and maintain a log of this information. Controlled substance prescription forms shall be shipped only to the prescribers address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California.
(i)Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three years.
(j)Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
(k)Security printers shall report any theft or loss of controlled substance prescription forms to the Department of Justice via fax or email within 24 hours of the theft or loss.
(l)(1)The department shall impose restrictions, sanctions, or penalties, subject to subdivisions (m) and (n), against security printers who are not in compliance with this division pursuant to regulations implemented pursuant to this division and shall revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
(2)When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
(m)The following violations by security printers shall be punishable pursuant to subdivision (n):
(1)Failure to comply with the Security Printer Guidelines established by the Security Printer Program as a condition of approval.
(2)Failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms.
(3)Theft or fraudulent use of a prescribers identity in order to obtain security prescription forms.
(n)A security printer approved pursuant to subdivision (b) shall be subject to the following penalties for actions leading to the denial of a security printer application specified in subdivision (d) or for a violation specified in subdivision (m):
(1)For a first violation, a fine not to exceed one thousand dollars ($1,000).
(2)For a second or subsequent violation, a fine not to exceed two thousand five hundred dollars ($2,500) for each violation.
(3)For a third or subsequent violation, a filing of an administrative disciplinary action seeking to suspend or revoke security printer approval.
(o)In order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, the Department of Justice may cease issuing new approvals of security printers to the extent necessary to achieve these purposes. The department may, pursuant to regulation, reduce the number of currently approved security printers to no fewer than three vendors. The department shall ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
SEC. 3.Section 11162.1 of the Health and Safety Code is amended to read:11162.1.(a)The prescription forms for controlled substances shall be printed with the following features:
(1)A latent, repetitive void pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word void shall appear in a pattern across the entire front of the prescription.
(2)A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words California Security Prescription.
(3)A chemical void protection that prevents alteration by chemical washing.
(4)A feature printed in thermochromic ink.
(5)An area of opaque writing so that the writing disappears if the prescription is lightened.
(6)A description of the security features included on each prescription form.
(7)(A)Six quantity check off boxes shall be printed on the form so that the prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
124
2549
5074
75100
101150
151 and over.
(B)In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
(8)Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the Prescription is void if the number of drugs prescribed is not noted.
(9)The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
(10)Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
(11)The date of origin of the prescription.
(12)A check box indicating the prescribers order not to substitute.
(13)An identifying number assigned to the approved security printer by the Department of Justice.
(14)(A)A check box by the name of each prescriber when a prescription form lists multiple prescribers.
(B)Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
(15)A uniquely serialized number, in a manner prescribed by the Department of Justice.
(b)Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
(c)(1)A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
(2)Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in Section 1206 that has 25 or more physicians or surgeons preprinted on the form. Licensed health care facilities or clinics exempt under Section 1206 are not required to preprint the category of licensure and license number of their facility or clinic.
(3)Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
(4)(A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and quantity of controlled substance prescription forms issued to each prescriber. The record shall be maintained in the health facility for three years.
(B)Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescribers name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
(d)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:
(1)Serial numbers of all prescription forms delivered.
(2)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
(3)The delivery shipment recipient names.
(4)The date of delivery.
SEC. 4.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
SEC. 4.5.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, if patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)The Department of Justice shall, no later than July 1, 2020, adopt regulations regarding the access and use of the information within CURES. The Department of Justice shall consult with all stakeholders identified by the department during the rulemaking process. The regulations shall, at a minimum, address all of the following in a manner consistent with this chapter:
(A)The process for approving, denying, and disapproving individuals or entities seeking access to information in CURES.
(B)The purposes for which a health care practitioner may access information in CURES.
(C)The conditions under which a warrant, subpoena, or court order is required for a law enforcement agency to obtain information from CURES as part of a criminal investigation.
(D)The process by which information in CURES may be provided for educational, peer review, statistical, or research purposes.
(4)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data are provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility, if provided.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
(h)(1)The Department of Justice may enter into an agreement with any entity operating an interstate data sharing hub, or any agency operating a prescription drug monitoring program in another state, for purposes of interstate data sharing of prescription drug monitoring program information.
(2)Data obtained from CURES may be provided to authorized users of another states prescription drug monitoring program, as determined by the Department of Justice pursuant to subdivision (c), if the entity operating the interstate data sharing hub, and the prescription drug monitoring program of that state, as applicable, have entered into an agreement with the Department of Justice for interstate data sharing of prescription drug monitoring program information.
(3)Any agreement entered into by the Department of Justice for purposes of interstate data sharing of prescription drug monitoring program information shall ensure that all access to data obtained from CURES and the handling of data contained within CURES comply with California law, including regulations, and meet the same patient privacy, audit, and data security standards employed and required for direct access to CURES.
(4)For purposes of interstate data sharing of CURES information pursuant to this subdivision, an authorized user of another states prescription drug monitoring program shall not be required to register with CURES, if he or she is registered and in good standing with that states prescription drug monitoring program.
(5)The Department of Justice shall not enter into an agreement pursuant to this subdivision until the department has issued final regulations regarding the access and use of the information within CURES as required by paragraph (3) of subdivision (c).
SEC. 5.Section 4.5 of this bill incorporates amendments to Section 11165 of the Health and Safety Code proposed by both this bill and Assembly Bill 1751. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2019, (2) each bill amends Section 11165 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 1751, in which case Section 4 of this bill shall not become operative.
The Legislature finds and declares the following:
(a)The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
(b)Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
(c)Many states have begun to require that all controlled substances be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
(d)Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
SEC. 2.Section 11161.5 of the Health and Safety Code is amended to read:11161.5.(a)Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
(b)The department may approve security printer applications after the applicant has provided the following information:
(1)Name, address, and telephone number of the applicant.
(2)Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
(3)Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
(4)(A)The location, names, and titles of the applicants agent for service of process in this state; all principal corporate officers, if any; all managing general partners, if any; and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms.
(B)A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, managing general partner, or of any person described in subparagraph (A).
(5)(A)A signed statement indicating whether the applicant, any principal corporate officer, any managing general partner, or any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, has ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.
(B)The department shall provide the applicant and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.
(C)Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (l) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
(D)The department shall assess against each security printer applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks and inspections of security printers pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits the security printer application, fingerprints, and related information to the department.
(E)The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
(c)The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
(d)The department may deny a security printer application on any of the following grounds:
(1)The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.
(2)The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
(3)The applicant committed any act that would constitute a violation of this division.
(4)The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
(5)The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
(6)The department determines that the applicant has submitted an incomplete application.
(7)As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
(e)An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
(f)The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
(g)Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances with the federal Drug Enforcement Administration (DEA).
(h)Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by a means that requires a signature signifying receipt of the package and provision of that signature to the security printer. Controlled substance prescription forms provided in person shall be restricted to established customers. Security printers shall obtain a photo identification from the customer and maintain a log of this information. Controlled substance prescription forms shall be shipped only to the prescribers address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California.
(i)Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three years.
(j)Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
(k)Security printers shall report any theft or loss of controlled substance prescription forms to the Department of Justice via fax or email within 24 hours of the theft or loss.
(l)(1)The department shall impose restrictions, sanctions, or penalties, subject to subdivisions (m) and (n), against security printers who are not in compliance with this division pursuant to regulations implemented pursuant to this division and shall revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
(2)When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
(m)The following violations by security printers shall be punishable pursuant to subdivision (n):
(1)Failure to comply with the Security Printer Guidelines established by the Security Printer Program as a condition of approval.
(2)Failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms.
(3)Theft or fraudulent use of a prescribers identity in order to obtain security prescription forms.
(n)A security printer approved pursuant to subdivision (b) shall be subject to the following penalties for actions leading to the denial of a security printer application specified in subdivision (d) or for a violation specified in subdivision (m):
(1)For a first violation, a fine not to exceed one thousand dollars ($1,000).
(2)For a second or subsequent violation, a fine not to exceed two thousand five hundred dollars ($2,500) for each violation.
(3)For a third or subsequent violation, a filing of an administrative disciplinary action seeking to suspend or revoke security printer approval.
(o)In order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, the Department of Justice may cease issuing new approvals of security printers to the extent necessary to achieve these purposes. The department may, pursuant to regulation, reduce the number of currently approved security printers to no fewer than three vendors. The department shall ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
SEC. 3.Section 11162.1 of the Health and Safety Code is amended to read:11162.1.(a)The prescription forms for controlled substances shall be printed with the following features:
(1)A latent, repetitive void pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word void shall appear in a pattern across the entire front of the prescription.
(2)A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words California Security Prescription.
(3)A chemical void protection that prevents alteration by chemical washing.
(4)A feature printed in thermochromic ink.
(5)An area of opaque writing so that the writing disappears if the prescription is lightened.
(6)A description of the security features included on each prescription form.
(7)(A)Six quantity check off boxes shall be printed on the form so that the prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
124
2549
5074
75100
101150
151 and over.
(B)In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
(8)Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the Prescription is void if the number of drugs prescribed is not noted.
(9)The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
(10)Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
(11)The date of origin of the prescription.
(12)A check box indicating the prescribers order not to substitute.
(13)An identifying number assigned to the approved security printer by the Department of Justice.
(14)(A)A check box by the name of each prescriber when a prescription form lists multiple prescribers.
(B)Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
(15)A uniquely serialized number, in a manner prescribed by the Department of Justice.
(b)Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
(c)(1)A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
(2)Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in Section 1206 that has 25 or more physicians or surgeons preprinted on the form. Licensed health care facilities or clinics exempt under Section 1206 are not required to preprint the category of licensure and license number of their facility or clinic.
(3)Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
(4)(A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and quantity of controlled substance prescription forms issued to each prescriber. The record shall be maintained in the health facility for three years.
(B)Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescribers name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
(d)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:
(1)Serial numbers of all prescription forms delivered.
(2)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
(3)The delivery shipment recipient names.
(4)The date of delivery.
SEC. 4.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
SEC. 4.5.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, if patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)The Department of Justice shall, no later than July 1, 2020, adopt regulations regarding the access and use of the information within CURES. The Department of Justice shall consult with all stakeholders identified by the department during the rulemaking process. The regulations shall, at a minimum, address all of the following in a manner consistent with this chapter:
(A)The process for approving, denying, and disapproving individuals or entities seeking access to information in CURES.
(B)The purposes for which a health care practitioner may access information in CURES.
(C)The conditions under which a warrant, subpoena, or court order is required for a law enforcement agency to obtain information from CURES as part of a criminal investigation.
(D)The process by which information in CURES may be provided for educational, peer review, statistical, or research purposes.
(4)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data are provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility, if provided.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
(h)(1)The Department of Justice may enter into an agreement with any entity operating an interstate data sharing hub, or any agency operating a prescription drug monitoring program in another state, for purposes of interstate data sharing of prescription drug monitoring program information.
(2)Data obtained from CURES may be provided to authorized users of another states prescription drug monitoring program, as determined by the Department of Justice pursuant to subdivision (c), if the entity operating the interstate data sharing hub, and the prescription drug monitoring program of that state, as applicable, have entered into an agreement with the Department of Justice for interstate data sharing of prescription drug monitoring program information.
(3)Any agreement entered into by the Department of Justice for purposes of interstate data sharing of prescription drug monitoring program information shall ensure that all access to data obtained from CURES and the handling of data contained within CURES comply with California law, including regulations, and meet the same patient privacy, audit, and data security standards employed and required for direct access to CURES.
(4)For purposes of interstate data sharing of CURES information pursuant to this subdivision, an authorized user of another states prescription drug monitoring program shall not be required to register with CURES, if he or she is registered and in good standing with that states prescription drug monitoring program.
(5)The Department of Justice shall not enter into an agreement pursuant to this subdivision until the department has issued final regulations regarding the access and use of the information within CURES as required by paragraph (3) of subdivision (c).
SEC. 5.Section 4.5 of this bill incorporates amendments to Section 11165 of the Health and Safety Code proposed by both this bill and Assembly Bill 1751. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2019, (2) each bill amends Section 11165 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 1751, in which case Section 4 of this bill shall not become operative.
The Legislature finds and declares the following:
(a)The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
(b)Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
(c)Many states have begun to require that all controlled substances must be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
(d)Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
SEC. 2.Section 11161.5 of the Health and Safety Code is amended to read:11161.5.(a)Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
(b)The department may approve security printer applications after the applicant has provided the following information:
(1)Name, address, and telephone number of the applicant.
(2)Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
(3)Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
(4)(A)The location, names, and titles of the applicants agent for service of process in this state; all principal corporate officers, if any; all managing general partners, if any; and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms.
(B)A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, managing general partner, or of any person described in subparagraph (A).
(5)(A)A signed statement indicating whether the applicant, any principal corporate officer, any managing general partner, or any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, has ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.
(B)The department shall provide the applicant and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.
(C)Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (l) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
(D)The department shall assess against each security printer applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks and inspections of security printers pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits the security printer application, fingerprints, and related information to the department.
(E)The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
(c)The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
(d)The department may deny a security printer application on any of the following grounds:
(1)The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.
(2)The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
(3)The applicant committed any act that would constitute a violation of this division.
(4)The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
(5)The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
(6)The department determines that the applicant has submitted an incomplete application.
(7)As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
(e)An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
(f)The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
(g)Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances with the federal Drug Enforcement Administration (DEA).
(h)Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by a means that requires a signature signifying receipt of the package and provision of that signature to the security printer. Controlled substance prescription forms provided in person shall be restricted to established customers. Security printers shall obtain a photo identification from the customer and maintain a log of this information. Controlled substance prescription forms shall be shipped only to the prescribers address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California.
(i)Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three years.
(j)Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
(k)Security printers shall report any theft or loss of controlled substance prescription forms to the Department of Justice via fax or email within 24 hours of the theft or loss.
(l)(1)The department shall impose restrictions, sanctions, or penalties, subject to subdivisions (m) and (n), against security printers who are not in compliance with this division pursuant to regulations implemented pursuant to this division and shall revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
(2)When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
(m)The following violations by security printers shall be punishable pursuant to subdivision (n):
(1)Failure to comply with the Security Printer Guidelines established by the Security Printer Program as a condition of approval.
(2)Failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms.
(3)Theft or fraudulent use of a prescribers identity in order to obtain security prescription forms.
(n)A security printer approved pursuant to subdivision (b) shall be subject to the following penalties for actions leading to the denial of a security printer application specified in subdivision (d) or for a violation specified in subdivision (m):
(1)For a first violation, a fine not to exceed one thousand dollars ($1,000).
(2)For a second or subsequent violation, a fine not to exceed two thousand five hundred dollars ($2,500) for each violation.
(3)For a third or subsequent violation, a filing of an administrative disciplinary action seeking to suspend or revoke security printer approval.
(o)In order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, the Department of Justice may cease issuing new approvals of security printers to the extent necessary to achieve these purposes. The department may, pursuant to regulation, reduce the number of currently approved security printers to no fewer than three vendors. The department shall ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
SEC. 3.Section 11162.1 of the Health and Safety Code is amended to read:11162.1.(a)The prescription forms for controlled substances shall be printed with the following features:
(1)A latent, repetitive void pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word void shall appear in a pattern across the entire front of the prescription.
(2)A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words California Security Prescription.
(3)A chemical void protection that prevents alteration by chemical washing.
(4)A feature printed in thermochromic ink.
(5)An area of opaque writing so that the writing disappears if the prescription is lightened.
(6)A description of the security features included on each prescription form.
(7)(A)Six quantity check off boxes shall be printed on the form so that the prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
124
2549
5074
75100
101150
151 and over.
(B)In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
(8)Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the Prescription is void if the number of drugs prescribed is not noted.
(9)The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
(10)Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
(11)The date of origin of the prescription.
(12)A check box indicating the prescribers order not to substitute.
(13)An identifying number assigned to the approved security printer by the Department of Justice.
(14)(A)A check box by the name of each prescriber when a prescription form lists multiple prescribers.
(B)Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
(15)A uniquely serialized number, in a manner prescribed by the Department of Justice.
(b)Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
(c)(1)A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
(2)Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in Section 1206 that has 25 or more physicians or surgeons preprinted on the form. Licensed health care facilities or clinics exempt under Section 1206 are not required to preprint the category of licensure and license number of their facility or clinic.
(3)Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
(4)(A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and quantity of controlled substance prescription forms issued to each prescriber. The record shall be maintained in the health facility for three years.
(B)Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescribers name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
(d)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:
(1)Serial numbers of all prescription forms delivered.
(2)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
(3)The delivery shipment recipient names.
(4)The date of delivery.
SEC. 4.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
SEC. 4.5.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that if patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)The Department of Justice shall, no later than July 1, 2020, adopt regulations regarding the access and use of the information within CURES. The Department of Justice shall consult with all stakeholders identified by the department during the rulemaking process. The regulations shall, at a minimum, address all of the following in a manner consistent with this chapter:
(A)The process for approving, denying, and disapproving individuals or entities seeking access to information in CURES.
(B)The purposes for which a health care practitioner may access information in CURES.
(C)The conditions under which a warrant, subpoena, or court order is required for a law enforcement agency to obtain information from CURES as part of a criminal investigation.
(D)The process by which information in CURES may be provided for educational, peer review, statistical, or research purposes.
(3)(4)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is are provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility. facility, if provided.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
(h)(1)The Department of Justice may enter into an agreement with any entity operating an interstate data sharing hub, or any agency operating a prescription drug monitoring program in another state, for purposes of interstate data sharing of prescription drug monitoring program information.
(2)Data obtained from CURES may be provided to authorized users of another states prescription drug monitoring program, as determined by the Department of Justice pursuant to subdivision (c), if the entity operating the interstate data sharing hub, and the prescription drug monitoring program of that state, as applicable, have entered into an agreement with the Department of Justice for interstate data sharing of prescription drug monitoring program information.
(3)Any agreement entered into by the Department of Justice for purposes of interstate data sharing of prescription drug monitoring program information shall ensure that all access to data obtained from CURES and the handling of data contained within CURES comply with California law, including regulations, and meet the same patient privacy, audit, and data security standards employed and required for direct access to CURES.
(4)For purposes of interstate data sharing of CURES information pursuant to this subdivision, an authorized user of another states prescription drug monitoring program shall not be required to register with CURES, if he or she is registered and in good standing with that states prescription drug monitoring program.
(5)The Department of Justice shall not enter into an agreement pursuant to this subdivision until the department has issued final regulations regarding the access and use of the information within CURES as required by paragraph (3) of subdivision (c).
SEC. 5.Section 4.5 of this bill incorporates amendments to Section 11165 of the Health and Safety Code proposed by both this bill and Assembly Bill 1751. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2019, (2) each bill amends Section 11165 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 1751, in which case Section 4 of this bill shall not become operative.
The Legislature finds and declares the following:
(a)The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
(b)Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
(c)Many states have begun to require that all controlled substances must be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
(d)Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
SEC. 2.Section 11161.5 of the Health and Safety Code is amended to read:11161.5.(a)Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
(b)The department may approve security printer applications after the applicant has provided the following information:
(1)Name, address, and telephone number of the applicant.
(2)Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
(3)Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
(4)(A)The location, names, and titles of the applicants agent for service of process in this state; all principal corporate officers, if any; all managing general partners, if any; and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms.
(B)A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, managing general partner, or of any person described in subparagraph (A).
(5)(A)A signed statement indicating whether the applicant, any principal corporate officer, any managing general partner, or any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, has ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.
(B)The department shall provide the applicant and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.
(C)Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (l) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
(D)The department shall assess against each security printer applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks and inspections of security printers pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits the security printer application, fingerprints, and related information to the department.
(E)The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
(c)The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
(d)The department may deny a security printer application on any of the following grounds:
(1)The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.
(2)The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
(3)The applicant committed any act that would constitute a violation of this division.
(4)The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
(5)The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
(6)The department determines that the applicant has submitted an incomplete application.
(7)As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
(e)An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
(f)The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
(g)Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances with the federal Drug Enforcement Administration (DEA).
(h)Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by a means that requires a signature signifying receipt of the package and provision of that signature to the security printer. Controlled substance prescription forms provided in person shall be restricted to established customers. Security printers shall obtain a photo identification from the customer and maintain a log of this information. Controlled substance prescription forms shall be shipped only to the prescribers address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California.
(i)Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three years.
(j)Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
(k)Security printers shall report any theft or loss of controlled substance prescription forms to the Department of Justice via fax or e-mail email within 24 hours of the theft or loss.
(l)(1)The department shall impose restrictions, sanctions, or penalties, subject to subdivisions (m) and (n), against security printers who are not in compliance with this division pursuant to regulations implemented pursuant to this division and shall revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
(2)When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
(m)The following violations by security printers shall be punishable pursuant to subdivision (n):
(1)Failure to comply with the Security Printer Guidelines established by the Security Printer Program as a condition of approval.
(2)Failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms.
(3)Theft or fraudulent use of a prescribers identity in order to obtain security prescription forms.
(n)A security printer approved pursuant to subdivision (b) shall be subject to the following penalties for actions leading to the denial of a security printer application specified in subdivision (d) or for a violation specified in subdivision (m):
(1)For a first violation, a fine not to exceed one thousand dollars ($1,000).
(2)For a second or subsequent violation, a fine not to exceed two thousand five hundred dollars ($2,500) for each violation.
(3)For a third or subsequent violation, a filing of an administrative disciplinary action seeking to suspend or revoke security printer approval.
(o)Beginning January 1, 2020, the Department of Justice shall limit the number of approved printers to three. The Department of Justice shall establish policies governing the selection of the three approved vendors based on ability to meet demand and prevent fraud and theft of prescription pads and the process of revoking approval for currently authorized printers in excess of three.(o)In order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, the Department of Justice may cease issuing new approvals of security printers to the extent necessary to achieve these purposes. The department may, pursuant to regulation, reduce the number of currently approved security printers to no fewer than three vendors. The department shall ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
SEC. 3.Section 11162.1 of the Health and Safety Code is amended to read:11162.1.(a)The prescription forms for controlled substances shall be printed with the following features:
(1)A latent, repetitive void pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word void shall appear in a pattern across the entire front of the prescription.
(2)A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words California Security Prescription.
(3)A chemical void protection that prevents alteration by chemical washing.
(4)A feature printed in thermochromic ink.
(5)An area of opaque writing so that the writing disappears if the prescription is lightened.
(6)A description of the security features included on each prescription form.
(7)(A)Six quantity check off boxes shall be printed on the form so that the prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
124
2549
5074
75100
101150
151 and over.
(B)In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
(8)Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the Prescription is void if the number of drugs prescribed is not noted.
(9)The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
(10)Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
(11)The date of origin of the prescription.
(12)A check box indicating the prescribers order not to substitute.
(13)An identifying number assigned to the approved security printer by the Department of Justice.
(14)(A)A check box by the name of each prescriber when a prescription form lists multiple prescribers.
(B)Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
(15)(A)A uniquely serialized number, in a manner prescribed by the Department of Justice.
(B)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:(i)Serial numbers of all prescription forms delivered.(ii)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.(iii)The delivery shipment recipient names.(b)Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
(c)(1)A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
(2)Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in Section 1206 that has 25 or more physicians or surgeons preprinted on the form. Licensed health care facilities or clinics exempt under Section 1206 are not required to preprint the category of licensure and license number of their facility or clinic.
(3)Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
(4)(A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and quantity of controlled substance prescription forms issued to each prescriber. The record shall be maintained in the health facility for three years.
(B)Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescribers name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
(d)This section shall become operative on January 1, 2012. Prescription forms not in compliance with this division shall not be valid or accepted after July 1, 2012.(d)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:
(1)Serial numbers of all prescription forms delivered.
(2)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
(3)The delivery shipment recipient names.
(4)The date of delivery.
SEC. 4.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription pad, form, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
The Legislature finds and declares the following:
(a)The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
(b)Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
(c)Many states have begun to require that all controlled substances must be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
(d)Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
SEC. 2.Section 11161.5 of the Health and Safety Code is amended to read:11161.5.(a)Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
(b)The department may approve security printer applications after the applicant has provided the following information:
(1)Name, address, and telephone number of the applicant.
(2)Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
(3)Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
(4)(A)The location, names, and titles of the applicants agent for service of process in this state; all principal corporate officers, if any; all managing general partners, if any; and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms.
(B)A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, managing general partner, or of any person described in subparagraph (A).
(5)(A)A signed statement indicating whether the applicant, any principal corporate officer, any managing general partner, or any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, has ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.
(B)The department shall provide the applicant and any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor of the applicant who has direct access to, or management or control of, controlled substance prescription forms, with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.
(C)Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (l) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
(D)The department shall assess against each security printer applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks and inspections of security printers pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits the security printer application, fingerprints, and related information to the department.
(E)The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
(c)The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
(d)The department may deny a security printer application on any of the following grounds:
(1)The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of a conviction may be taken when the time for appeal has elapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.
(2)The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
(3)The applicant committed any act that would constitute a violation of this division.
(4)The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
(5)The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
(6)The department determines that the applicant has submitted an incomplete application.
(7)As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
(e)An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
(f)The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
(g)Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances with the federal Drug Enforcement Administration (DEA).
(h)Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by a means that requires a signature signifying receipt of the package and provision of that signature to the security printer. Controlled substance prescription forms provided in person shall be restricted to established customers. Security printers shall obtain a photo identification from the customer and maintain a log of this information. Controlled substance prescription forms shall be shipped only to the prescribers address on file and verified with the federal Drug Enforcement Administration or the Medical Board of California.
(i)Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three years.
(j)Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
(k)Security printers shall report any theft or loss of controlled substance prescription forms to the Department of Justice via fax or e-mail within 24 hours of the theft or loss.
(l)(1)The department shall impose restrictions, sanctions, or penalties, subject to subdivisions (m) and (n), against security printers who are not in compliance with this division pursuant to regulations implemented pursuant to this division and shall revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
(2)When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
(m)The following violations by security printers shall be punishable pursuant to subdivision (n):
(1)Failure to comply with the Security Printer Guidelines established by the Security Printer Program as a condition of approval.
(2)Failure to take reasonable precautions to prevent any dishonest act or illegal activity related to the access and control of security prescription forms.
(3)Theft or fraudulent use of a prescribers identity in order to obtain security prescription forms.
(n)A security printer approved pursuant to subdivision (b) shall be subject to the following penalties for actions leading to the denial of a security printer application specified in subdivision (d) or for a violation specified in subdivision (m):
(1)For a first violation, a fine not to exceed one thousand dollars ($1,000).
(2)For a second or subsequent violation, a fine not to exceed two thousand five hundred dollars ($2,500) for each violation.
(3)For a third or subsequent violation, a filing of an administrative disciplinary action seeking to suspend or revoke security printer approval.
(o)Beginning January 1, 2020, the Department of Justice shall limit the number of approved printers to three. The Department of Justice shall establish policies governing the selection of the three approved vendors based on ability to meet demand and prevent fraud and theft of prescription pads and the process of revoking approval for currently authorized printers in excess of three.
SEC. 3.Section 11162.1 of the Health and Safety Code is amended to read:11162.1.(a)The prescription forms for controlled substances shall be printed with the following features:
(1)A latent, repetitive void pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word void shall appear in a pattern across the entire front of the prescription.
(2)A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words California Security Prescription.
(3)A chemical void protection that prevents alteration by chemical washing.
(4)A feature printed in thermochromic ink.
(5)An area of opaque writing so that the writing disappears if the prescription is lightened.
(6)A description of the security features included on each prescription form.
(7)(A)Six quantity check off boxes shall be printed on the form so that the prescriber may indicate the quantity by checking the applicable box where the following quantities shall appear:
124
2549
5074
75100
101150
151 and over.
(B)In conjunction with the quantity boxes, a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
(8)Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the Prescription is void if the number of drugs prescribed is not noted.
(9)The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
(10)Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
(11)The date of origin of the prescription.
(12)A check box indicating the prescribers order not to substitute.
(13)An identifying number assigned to the approved security printer by the Department of Justice.
(14)(A)A check box by the name of each prescriber when a prescription form lists multiple prescribers.
(B)Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
(15)(A)A uniquely serialized number, in a manner prescribed by the Department of Justice.
(B)Within the next working day following delivery, a security printer shall submit via Web-based application, as specified by the Department of Justice, all of the following information for all prescription forms delivered:
(i)Serial numbers of all prescription forms delivered.
(ii)All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
(iii)The delivery shipment recipient names.
(b)Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
(c)(1)A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
(2)Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in Section 1206 that has 25 or more physicians or surgeons preprinted on the form. Licensed health care facilities or clinics exempt under Section 1206 are not required to preprint the category of licensure and license number of their facility or clinic.
(3)Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
(4)(A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and quantity of controlled substance prescription forms issued to each prescriber. The record shall be maintained in the health facility for three years.
(B)Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescribers name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
(d)This section shall become operative on January 1, 2012. Prescription forms not in compliance with this division shall not be valid or accepted after July 1, 2012.
SEC. 4.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(11)The serial number for the corresponding prescription pad, if applicable.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
|
Date
|
Status
|
|---|---|
| Sep 18, 2018 | Chaptered by Secretary of State - Chapter 479, Statutes of 2018. |
| Sep 18, 2018 | Approved by the Governor. |
| Sep 10, 2018 | Enrolled and presented to the Governor at 3:30 p.m. |
| Aug 30, 2018 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 29, 2018 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 29, 2018 | Read third time. Passed. Ordered to the Assembly. |
| Aug 27, 2018 | Read second time. Ordered to third reading. |
| Aug 24, 2018 | Read third time and amended. Ordered to second reading. |
| Aug 17, 2018 | From committee: Do pass. (Ayes 7. Noes 0.) (August 16). |
| Aug 6, 2018 | In committee: Referred to APPR. suspense file. |
| Jun 26, 2018 | From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 7. Noes 0.) (June 26). Re-referred to Com. on APPR. |
| Jun 19, 2018 | From committee: Do pass and re-refer to Com. on PUB. S. (Ayes 9. Noes 0.) (June 18). Re-referred to Com. on PUB. S. |
| Jun 7, 2018 | Referred to Coms. on B., P. & E.D. and PUB. S. |
| May 30, 2018 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 29, 2018 | Read third time. Passed. Ordered to the Senate. |
| May 25, 2018 | From committee: Do pass. (Ayes 16. Noes 0.) (May 25). |
| May 2, 2018 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 25, 2018 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (April 24). Re-referred to Com. on APPR. |
| Apr 19, 2018 | Re-referred to Com. on PUB. S. |
| Apr 18, 2018 | From committee chair, with author's amendments: Amend, and re-refer to Com. on PUB. S. Read second time and amended. |
| Apr 10, 2018 | From committee: Do pass and re-refer to Com. on PUB. S. (Ayes 15. Noes 1.) (April 10). Re-referred to Com. on PUB. S. |
| Jan 16, 2018 | Referred to Coms. on B. & P. and PUB. S. |
| Jan 4, 2018 | From printer. May be heard in committee February 3. |
| Jan 3, 2018 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 30, 2018 | AB 1753 LOW Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 29, 2018 | Assembly 3rd Reading AB1753 Low By Bates | Senate Floor |
Passed |
|
| Aug 16, 2018 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 6, 2018 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 26, 2018 | Do pass, but first be re-referred to the Committee on [Appropriations] with the recommendation: To Consent Calendar | Senate Standing Committee on Public Safety |
Passed |
|
| Jun 18, 2018 | Do pass, but first be re-referred to the Committee on [Public Safety] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| May 29, 2018 | AB 1753 LOW Assembly Third Reading | Assembly Floor |
Passed |
|
| May 25, 2018 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 24, 2018 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Public Safety |
Passed |
|
| Apr 10, 2018 | Do pass and be re-referred to the Committee on [Public Safety] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1753
Author:(Low)
As Amended Ver:August 24, 2018
Majority vote
ASSEMBLY: | 76-0 | (May 29, 2018) | SENATE: | 39-0 | (August 29, 2018) |
Original Committee Reference: B. & P.
SUMMARY: Authorizes the Department of Justice (COJ) to cap the number of security printers approved to manufacture regulated prescription pads to three and allows DOJ to reduce or limit the number of printers to no fewer than three through regulation; requires that all prescription forms be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the state's prescription drug monitoring program (PDMP), Controlled substance Utilization Review and Evaluation System (CURES).
The Senate amendments add chaptering language to resolve potential conflicts with AB 1751 (Low) of the current legislative session.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code Section (HSC) 11150)
- Requires that all prescription forms for controlled substance prescriptions be obtained from security printers approved by the DOJ and sets a number of parameters for the DOJ's approval process. (HSC 11161.5)
- Provides that when a prescriber's authority to prescribe controlled substances is restricted, the law enforcement agency or licensing board that sought the restrictions shall provide the prescriber's name, category of licensure, license number, and the nature of the restrictions imposed on the prescriber to security printers, the DOJ, and the Board of Pharmacy. (HSC 11161.7)
- Lists a number of required features that must be included for all prescription forms for controlled substances, including fraud-prevention identifiers, printing information, and information relating to the prescribing practitioner. (HSC 11162.1)
- Criminalizes the counterfeiting of prescription pads and the possession of counterfeit prescription pads. (HSC 11162.5 to 11162.6)
- Requires all prescriptions and dispensations of controlled substances to meet a series of requirements including use of a controlled substance prescription form, presence of a signature and date in ink, and the address of the patient. (HSC 11164)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC 11173)
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC 11165.3)
FISCAL EFFECT: According to the Senate Committee on Appropriations, one-time costs of $884,000 for the development of the web-based application, contract with the Department of Technology for external project approval, oversight, and tracking, network costs, and departmental services.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
The opioid crisis ravaging communities throughout our nation and California must first and foremost be addressed through solutions rooted in a public health approach. However, prescription drug abuse and diversion continues to be a pressing public safety issue as well. As instances of addiction to pharmaceutical opioids grows, criminal enterprises derive tremendous profit through prescription pad theft and fraud. Because current statute provides for little effective regulation of dozens of security printers entrusted with manufacturing these pads, it is challenging for law enforcement to track prescriptions that may have been written with counterfeit or stolen pads. AB 1753 will tighten existing controls involved in the security printers program and ensure that prescriptions filled using illicit pads can be linked to prescription data collected through the successful CURES database.
Background.
Security Printers and Prescription Pads. Under the DOJ's Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant's name, address, and telephone number along with a description of the applicant's intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant's business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
All prescription forms are required to contain a number of security features and identifying markers. However, this does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.
One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.
Allowing the DOJ to cap the number of approved security printers and reduce the number through regulation to three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0005157
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 1753
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 6/18/18
AYES: Hill, Fuller, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
SENATE PUBLIC SAFETY COMMITTEE: 7-0, 6/26/18
AYES: Skinner, Anderson, Bradford, Jackson, Mitchell, Stone, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/16/18
AYES: Portantino, Bates, Beall, Bradford, Hill, Nielsen, Wiener
ASSEMBLY FLOOR: 76-0, 5/29/18 - See last page for vote
DIGEST:
This bill allows the Department of Justice (DOJ) to cap the number of security printers approved to manufacture regulated prescription pads and reduce the current number by regulation to no fewer than three; requires that all prescription be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the Controlled Substances Utilization Review and Evaluation System (CURES) prescription drug monitoring database when available.
Senate Floor Amendments of 8/24/18 resolve chaptering conflicts with AB 1751 (Low).
Existing law:
- Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the DOJ no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
This bill
- Authorizes DOJ, in order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, to cease issuing new approvals of security printers to the extent necessary to achieve these purposes.
- Authorizes DOJ, pursuant to regulation, to reduce the number of currently approved security printers to no fewer than three vendors.
- Requires DOJ to ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
Background
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Comments
The author notes that “One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.”
According to the author, “Allowing the DOJ to cap the number of approved security printers and reduce the list to no fewer than three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.”
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
According to the Senate Appropriations Committee, this bill will result in $966,000 General Fund in Fiscal Year (FY) 2019-20 and $180,000 General Fund in FY 2019-20 and ongoing; operations costs of $884,000 General Fund for a one-time external consultant ($221,000 General Fund) for the development of the web-based application, contract with the Department of Technology for external project approval, oversight, and tracking ($83,000), network costs ($475,000 General Fund), and departmental services costs ($105,000).
America’s Physician Groups
California Association of Code Enforcement Officers
California Association of Health Underwriters
California Chiropractic Association
California College and University Police Chiefs Association
California District Attorneys Association
California Life Sciences Association
California Narcotic Officers Association
California Police Chiefs Association
California State Board of Pharmacy
Consumer Attorneys of California
County Behavioral Health Directors Association of California
Los Angeles County Professional Peace Officers Association
OCHIN
Office of the District Attorney of San Diego County
Troy and Alana Pack Foundation
OPPOSITION: (Verified 8/24/18)
None received
ARGUMENTS IN SUPPORT: Supporters believe this bill will empower the DOJ in regulating private vendors entrusted with manufacturing prescription pads by adding new controls, limiting the number of approved printers, and linking unique serial numbers to CURES. According to supporters, this bill will help reduce prescription form forgery and fraud, which will help prevent prescription drug abuse. Supporters call this bill a positive step towards eliminating illicit sources of prescription opioids.
ASSEMBLY FLOOR: 76-0, 5/29/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Calderon, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Flora, Fong, Frazier, Friedman, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez Fletcher, Gray, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Quirk-Silva, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Eggman, Kamlager-Dove
8/27/18 19:41:07
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 1753
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 6/18/18
AYES: Hill, Fuller, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
SENATE PUBLIC SAFETY COMMITTEE: 7-0, 6/26/18
AYES: Skinner, Anderson, Bradford, Jackson, Mitchell, Stone, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/16/18
AYES: Portantino, Bates, Beall, Bradford, Hill, Nielsen, Wiener
ASSEMBLY FLOOR: 76-0, 5/29/18 - See last page for vote
DIGEST:
This bill allows the Department of Justice (DOJ) to cap the number of security printers approved to manufacture regulated prescription pads and reduce the current number by regulation to no fewer than three; requires that all prescription be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the Controlled Substances Utilization Review and Evaluation System (CURES) prescription drug monitoring database when available.
Existing law:
- Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the DOJ no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
This bill
- Authorizes DOJ, in order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, to cease issuing new approvals of security printers to the extent necessary to achieve these purposes.
- Authorizes DOJ, pursuant to regulation, to reduce the number of currently approved security printers to no fewer than three vendors.
- Requires DOJ to ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
Background
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Comments
The author notes that “One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.”
According to the author, “Allowing the DOJ to cap the number of approved security printers and reduce the list to no fewer than three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.”
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
According to the Senate Appropriations Committee, this bill will result in $966,000 General Fund in Fiscal Year (FY) 2019-20 and $180,000 General Fund in FY 2019-20 and ongoing; operations costs of $884,000 General Fund for a one-time external consultant ($221,000 General Fund) for the development of the web-based application, contract with the Department of Technology for external project approval, oversight, and tracking ($83,000), network costs ($475,000 General Fund), and departmental services costs ($105,000).
America’s Physician Groups
California Association of Code Enforcement Officers
California Association of Health Underwriters
California Chiropractic Association
California College and University Police Chiefs Association
California District Attorneys Association
California Life Sciences Association
California Narcotic Officers Association
California Police Chiefs Association
California State Board of Pharmacy
Consumer Attorneys of California
County Behavioral Health Directors Association of California
Los Angeles County Professional Peace Officers Association
OCHIN
Office of the District Attorney of San Diego County
Troy and Alana Pack Foundation
OPPOSITION: (Verified 8/17/18)
None received
ARGUMENTS IN SUPPORT: Supporters believe this bill will empower the DOJ in regulating private vendors entrusted with manufacturing prescription pads by adding new controls, limiting the number of approved printers, and linking unique serial numbers to CURES. According to supporters, this bill will help reduce prescription form forgery and fraud, which will help prevent prescription drug abuse. Supporters call this bill a positive step towards eliminating illicit sources of prescription opioids.
ASSEMBLY FLOOR: 76-0, 5/29/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Calderon, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Flora, Fong, Frazier, Friedman, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez Fletcher, Gray, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Quirk-Silva, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Eggman, Kamlager-Dove
8/18/18 13:45:42
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2017 - 2018 Regular Session
AB 1753 (Low) - Controlled substances: CURES database
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
- Authorizes the Department of Justice (DOJ) to, by regulation, reduce the number of approved security printers that manufacture regulated prescription pads to no fewer than three vendors. Makes other notification changes for security printers and dispensers to report serial numbers on prescription forms to the DOJ.
Fiscal Impact:
The Department of Justice estimates the following:
- $966,000 General Fund and in FY 2019-20 and $180,000 General Fund in FY 2019-20 and ongoing. In FY 2018-19 costs: 1.0 PY and operations costs of $884,000 General Fund for a one-time external consultant ($221,000 General Fund) for the development of the web-based application, contract with the Department of Technology for external project approval, oversight, and tracking ($83,000), network costs ($475,000 General Fund), and departmental services costs ($105,000).
Background:
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors that wish to operate as approved security printers must apply to the DOJ and provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Proposed Law:
Assembly Bill 173 includes the following provisions, among others:
- Authorizes the Department of Justice (DOJ) to, by regulation, reduce the number of approved security printers that manufacture regulated prescription pads to no fewer than three vendors.
- Requires all prescription forms to be uniquely serialized, in a manner prescribed by the DOJ.
- Requires a security printer, within the next working day following delivery, to submit via a Web-based application, as specified by the DOJ, all the following information for all prescription forms delivered:
- Serial numbers of all prescription forms delivered.
- All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms.
- The delivery shipment recipient names.
- The date of delivery.
- Requires the dispensing pharmacy, clinic, or other dispenser to report the serial number for the corresponding prescription form, if applicable, to the DOJ for each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined, as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed.
Related Legislation: The Legislature has considered similar CURES-related legislation in recent past, including:
- SB 1240 (Stone) expands the drugs required to be reported and monitored in CURES to include all dangerous drugs and Schedule V controlled substances and requires inclusion of a description of the diagnosis, condition, or purpose for which the prescription was issued and the directions for use to the list of information pharmacies are required to report to CURES for each prescription. The bill was not heard at the request of the author in the Senate Business, Professions, and Economic Development Committee.
- AB 1752 (Low) adds Schedule V drugs to CURES, changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day, and makes other technical changes. This bill is being considered by this committee at its August 6, 2018 hearing.
- AB 1753 (Low) would limit the number of security printers authorized to manufacture prescription pads and linking uniquely serialized pads with CURES. This bill is being considered by this committee at its August 6, 2018 hearing.
- AB 2086 (Gallagher) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber. The bill is pending on the Senate Floor.
- AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance schedules. (Status: The bill is pending in the Senate Committee on Public Safety.)
- AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions. This bill is being considered by this committee at its August 6, 2018 hearing.
-- END --
SENATE COMMITTEE ON PUBLIC SAFETY
Senator Nancy Skinner, Chair
2017 - 2018 Regular
Bill No: AB 1753 Hearing Date: June 26, 2018
Author: | Low | ||
Version: | April 18, 2018 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | SJ | ||
Subject: Controlled Substances: CURES Database
HISTORY
Source: Author
Prior Legislation: AB 40 (Santiago), Ch. 607, Stats. 2017
SB 641 (Lara), was not heard in Assembly Public Safety 2017
SB 482 (Lara), Ch. 708. Stats. 2016
SB 809 (De Saulnier), Ch. 400, Stats. 2013
SB 360 (De Saulnier), Ch.418, Stats. 2011
SB 151 (Burton), Ch. 406, Stats. 2003
AB 3042 (Takasugi), Ch.738, Stats. 1996
Support: America’s Physicians Group; California Association of Health Underwriters; California Chiropractic Association; California District Attorneys Association; California Life Sciences Association; California Police Chiefs Association; Consumer Attorneys of California; County Behavioral Health Directors Association of California; San Diego County District Attorney; Troy and Alana Pack Foundation
Opposition: None known
Assembly Floor Vote: 76 - 0
PURPOSE
The purpose of this bill is to authorize the Department of Justice (DOJ) to reduce or limit the number of approved controlled substance prescription security printers, as specified, and to require prescription forms for controlled substance prescriptions to have a uniquely serialized number, as specified.
Existing law establishes the Uniform Controlled Substances Act which regulates controlled substances. (Health & Saf. Code, § 11000 et seq.)
Existing law categorizes controlled substances into five schedules based on their danger and potential for abuse. (Health & Saf. Code, §§ 11007; 11054-11058.)
Existing law defines “prescription” as “an oral order or electronic transmission prescription for a controlled substance given individually for the person(s) for whom prescribed, directly from the prescriber to the furnisher or indirectly by means of a written order of the prescriber.” (Health & Saf. Code, §11027, subd. (a).)
Existing law specifies which health care professionals may write or issues a prescription. (Health & Saf. Code, § 11150.)
Existing law specifies that a prescription for a controlled substance shall only be issued for a legitimate medical purpose and establishes responsibility for proper prescribing on the prescribing practitioner. States that a violation shall result in imprisonment for up to one year or a fine of up to $20,000, or both. (Health & Saf. Code, § 11153.)
Existing law requires that prescription forms for controlled substance prescriptions be obtained from security printers approved by the DOJ. (Health & Saf. Code, § 11161.5, subd. (a).)
Existing law requires controlled substance prescriptions to be made on the specified prescription form. (Health & Saf. Code, § 11164.)
Existing law requires that the prescription forms for controlled substances include certain features. (Health & Saf. Code, § 11162.1.)
Existing law establishes the Controlled Substance Utilization Review and Evaluation System (CURES) for electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the DOJ at the time prescriptions are dispensed. (Health & Saf. Code, § 11165.)
Existing law provides that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (Health & Saf. Code, § 11165, subd. (a).)
Existing law establishes privacy protections for patient data and specifies that CURES data can only be accessed by appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions. Specifies that CURES data shall also only be provided, as determined by DOJ, to other agencies or entities for educating practitioners and others, in lieu of disciplinary, civil or criminal actions. Authorizes non-identifying CURES data to be provided to public and private entities for education, research, peer review and statistical analysis. (Health & Saf. Code, § 11165, subd. (c).)
Existing law provides that pharmacies or clinics, in filling a prescription for a federally Scheduled II, III or IV drug, shall provide weekly information to DOJ including the patient's name, date of birth, the name, form, strength and quantity of the drug, and the pharmacy name, pharmacy number and the prescribing physician information. (Health & Saf. Code, § 11165, subd. (d).)
Existing law provides that a licensed health care practitioner eligible to prescribe Schedule II, III or IV controlled substances, or a pharmacist, shall apply to participate in the CURES PDMP by January 1, 2016. Authorizes DOJ to deny an application or suspend a subscriber for certain violations and falsifying information. Provides that the history of controlled substances dispensed to a patient based on CURES data that is received by a practitioner or pharmacist shall be considered medical information, subject to provisions of the Confidentiality of Medical Information Act. (Health & Saf. Code, § 11165.1.)
Existing law authorizes the DOJ to conduct audits of the CURES PDMP system and its users and create a system for issuing citations for violations. (Health & Saf. Code, 11165.2, subd. (a) & (b).)
Existing law requires a health care practitioner authorized to prescribe, order, administer, or furnish a controlled substance to consult the CURES database to review a patient’s controlled substance history, as specified. (Health & Saf. Code, § 11165.4.)
Existing law requires health practitioners who prescribe or administer a controlled substance classified in Schedule II to make a record containing the name and address of the patient, date, and the character, name, strength, and quantity of the controlled substance prescribed, as well as the pathology and purpose for which the controlled substance was administered or prescribed. (Health & Saf. Code, § 11190, subd. (a) and (b).)
Existing law requires prescribers who are authorized to dispense Schedule II, III or IV controlled substance in their office or place of practice to record and maintain information for three years for each such prescription that includes the patient's name, address, gender, and date of birth, prescriber's license and license number, federal controlled substance registration number, state medical license number, National Drug Code number of the controlled substance dispensed, quantity dispensed, diagnosis code, if available, and original date of dispensing. Requires that this information be provided to DOJ on a monthly basis. (Health & Saf. Code, § 11190, subd. (c).)
This bill makes the following legislative declarations and findings:
- The prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year, contributing to the prescription drug abuse crisis and fueling criminal enterprises engaged in drug diversion.
- Prescribing controlled substances by means of electronic transmission prescription, or e-prescribing, has long been considered the most effective way to combat prescription pad theft and fraud.
- Many states have begun to require that all controlled substances must be prescribed electronically as a means of addressing the public health and public safety crises associated with prescription drug abuse and diversion.
- Until mandatory e-prescribing is established in California, it is critical that tighter restrictions be placed on the manufacturing and tracking of prescription pads used within the state.
This bill authorizes DOJ, in order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, to cease issuing new approvals of security printers to the extent necessary to achieve these purposes.
This bill authorizes DOJ, pursuant to regulation, to reduce the number of currently approved security printers to no fewer than three vendors.
This bill requires DOJ to ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
This bill requires prescription forms for controlled substances to include a uniquely serialized number in a manner prescribed by the DOJ.
COMMENTS
- Need for This Bill
According to the author:
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
. . .
Th[e] list of requirements [for prescription pads] does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.
One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.
Allowing the DOJ to limit the number of approved security printers to no fewer than three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.
- Prescriptions
Written prescriptions have been regulated in the State of California since 1929, when a statute was first enacted to require that certain drugs be dispensed only with a written prescription from a licensed physician, dentist, or veterinarian. These prescriptions were required to include the name and address of the individual receiving the drug, and for three years all prescription records were required to remain “open to inspection by the prescriber and properly authorized officers of the law, including all inspectors of the division of narcotic enforcement and of the state board of pharmacy.” This requirement was later expanded to include all prescription drugs.
Under the DOJ’s Triplicate Prescription Program (TPP), first launched in 1939 under Attorney General Earl Warren, health practitioners were required to use serialized triplicate prescription forms when prescribing a Schedule II controlled substance. One copy was provided to the patient, and another was retained for the prescriber’s records. The third copy of each triplicated prescription was sent to the Bureau of Narcotics Enforcement within the DOJ’s Division of Law Enforcement, which used the records to investigate potential fraud or criminal diversion of controlled substances. When the TPP was replaced by the CURES database in 2005, the triplicate prescription form requirement for Schedule II drugs was replaced with a new requirement that these prescriptions be issued on a special form obtained from an approved printer.
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may be fined or have their approval revoked for misconduct.
- CURES
Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and,
(c) their accepted safety under medical supervision.
Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD.
Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl and Oxycontin.
Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien and other anti-anxiety drugs.
Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99 percent) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Health practitioners will soon be required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed (DOJ certified the system for statewide use on March 31, 2017; consultation requirements for prescribers outlined in SB 482 [Lara, Chapter 708, Statutes of 2016] take effect six months after DOJ certifies the system). Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
- Argument in Support
The California Police Chiefs Association writes in support of AB 1751. According to Cal Chiefs, the bill would “empower the role of the Department of Justice in regulating private vendors entrusted with manufacturing prescription pads by adding new controls, limiting the number of approved printers, and linking unique serial numbers to CURES.” Cal Chiefs describes the bill as part of a larger effort to “fight back against the alarming opioid crisis affecting our state and nation.”
The District Attorney of San Diego County, Summer Stephan, supports the bill.
DA Stephan states that the bill “helps to further the administration of justice and promote safety in our community.” The California District Attorneys Association echoes this sentiment on behalf of all 58 county district attorneys. CDAA writes that the bill “would help reduce prescription form forgery and fraud, which will help prevent prescription drug abuse.”
The California Life Sciences Association supports AB 1753, representing the state’s biotechnology, pharmaceutical, medical device and diagnostics companies, venture capital firms, research universities, and nearly 30,000 employees in the industry. CLSA cites specific examples of criminal cases where the legislation would have aided law enforcement investigations: “For instance, in Modesto, a single four-person prescription fraud ring put over 50,000 prescription opioids on the street within a year, using stolen prescription pads and forged prescriptions.” CLSA writes that AB 1753 would be a “positive step towards eliminating illicit sources of prescription opioids.”
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2017 - 2018 Regular
Bill No: Hearing Date: June 18, 2018
Author: | |||
Version: | April 18, 2018 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Sarah Mason | ||
Subject:
SUMMARY: Allows the Department of Justice (DOJ) to cap the number of security printers approved to manufacture regulated prescription pads and reduce the current number by regulation to no fewer than three; requires that all prescription be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the Controlled Substances Utilization Review and Evaluation System (CURES) prescription drug monitoring database when available.
Existing law:
- Establishes various practice acts in the Business and Professions Code (BPC) governed by various boards within the Department of Consumer Affairs (DCA) which provide for the licensing and regulation of health care professionals including: physicians and surgeons (under the Medical Practice Act), dentists (under the Dental Practice Act), veterinarians (under the Veterinary Medicine Practice Act); registered nurses, nurse practitioners (NP) and certified nurse-midwives (CNM) (under the Nursing Practice Act); physician assistants (PA) (under the Physician Assistant Practice Act); osteopathic physicians and surgeons (under the Osteopathic Medical Practice Act); naturopathic doctors (ND) (under the Naturopathic Doctors Act); optometrists (under the Optometry Practice Act); doctors of podiatric medicine (under the Podiatric Act) and; pharmacies, pharmacists and wholesalers of dangerous drugs or devices (under the Pharmacy Law). (Business and Professions Code (BPC) §§ 500 et seq.)
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian or ND. (BPC § 4059)
- Establishes the Uniform Controlled Substances Act which regulates controlled substances and defines an opiate as any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. (Health and Safety Code (HSC) § 11020)
- Classifies controlled substances into five schedules according to their danger and potential for abuse. (HSC §§ 11054-11058)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), CNM (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), NP (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or PA acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance.
(HSC § 11150) - Requires that all prescription forms for controlled substance prescriptions be obtained from security printers approved by the DOJ and sets a number of parameters for the DOJ’s approval process. (HSC § 11161.5)
- Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (HSC § 11165 (a))
- Establishes privacy protections for patient data and specifies that the operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations. Specifies that CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Specifies that data obtained from CURES can only be accessed by appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions. Specifies that CURES data shall also only be provided, as determined by DOJ, to other agencies or entities for educating practitioners and others, in lieu of disciplinary, civil or criminal actions. Authorizes non-identifying CURES data to be provided to public and private entities for education, research, peer review and statistical analysis. Requires DOJ to establish policies, procedures and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165 (c) (1) and (c) (2) (A))
- Requires DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
This bill:
- Authorizes DOJ, in order to facilitate the standardization of all prescription forms and the serialization of prescription forms with unique identifiers, to cease issuing new approvals of security printers to the extent necessary to achieve these purposes.
- Authorizes DOJ, pursuant to regulation, to reduce the number of currently approved security printers to no fewer than three vendors.
- Requires DOJ to ensure that any reduction or limitation of approved security printers does not impact the ability of vendors to meet demand for prescription forms.
FISCAL EFFECT:
This bill is keyed fiscal by Legislative Counsel. According to the Assembly Committee on Appropriations analysis dated May 2, 2018, this bill will result in one-time costs of $900,000 in General Fund monies for DOJ to implement a web-based portal to collect information about prescription pads and include information CURES and ongoing costs in the range of $200,000 annually for ongoing information technology support for the new application.
COMMENTS:
- Purpose. The Author is the Sponsor of this bill. According to the Author, “The list of requirements for prescription pads does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.”
The Author notes that “One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.”
According to the Author, “Allowing the DOJ to cap the number of approved security printers and reduce the list to no fewer than three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.”
- Background.
Prescriptions. Written prescriptions have been regulated in the State of California since 1929, when a statute was first enacted to require that certain drugs be dispensed only with a written prescription from a licensed physician, dentist, or veterinarian. These prescriptions were required to include the name and address of the individual receiving the drug, and for three years all prescription records were required to remain “open to inspection by the prescriber and properly authorized officers of the law, including all inspectors of the division of narcotic enforcement and of the state board of pharmacy.” This requirement was later expanded to include all prescription drugs.
Under the DOJ’s Triplicate Prescription Program (TPP), first launched in 1939 under Attorney General Earl Warren, health practitioners were required to use serialized triplicate prescription forms when prescribing a Schedule II controlled substance. One copy was provided to the patient; another was retained for the prescriber’s records. The third copy of each triplicated prescription was sent to the Bureau of Narcotics Enforcement within the DOJ’s Division of Law Enforcement, which used the records to investigate potential fraud or criminal diversion of controlled substances. When the TPP was replaced by the CURES database in 2005, the triplicate prescription form requirement for Schedule II drugs was replaced with a new requirement that these prescriptions be issued on a special form obtained from an approved printer.
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Controlled Substances, PDMPs and CURES. Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and,
(c) their accepted safety under medical supervision.
Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD.
Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl and Oxycontin.
Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien and other anti-anxiety drugs.
Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99 percent) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Health practitioners will soon be required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed (DOJ certified the system for statewide use on March 31, 2017; consultation requirements for prescribers outlined in SB 482 [Lara, Chapter 708, Statutes of 2016] take effect six months after DOJ certifies the system). Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
- Related Legislation This Year. CURES has been the focus of ongoing discussions in the Legislature, as California and the nation face an epidemic of prescription drug abuse and related overdose deaths.
SB 1240 (Stone) expands the drugs required to be reported and monitored in CURES to include all dangerous drugs and Schedule V controlled substances and requires inclusion of a description of the diagnosis, condition, or purpose for which the prescription was issued and the directions for use to the list of information pharmacies are required to report to CURES for each prescription. (Status: This bill is also pending in this committee.)
AB 1751 (Low) provides a framework for CURES to connect with other states that comply with California’s patient privacy and data security standards. (Status: This bill is also pending in this committee.)
AB 1752 (Low) adds Schedule V drugs to CURES, changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day, and makes other technical changes. (Status: This bill is also pending in this committee.)
AB 2086 (Gallagher) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber. (Status: This bill is also pending in this committee.)
AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance
schedules. (Status: The bill is pending in the Senate Committee on Public Safety.)
AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions. (Status: This bill is also pending in this committee.)
- Prior Related Legislation. AB 40 (Santiago, Chapter 607, Statutes of 2017) authorized an entity that operates a health information technology system to establish an integration with, and submit queries to CURES on either a user-initiated basis or automated basis, according to certain requirements.
SB 641 (Lara) of 2016 would have prohibited the DOJ from releasing data in CURES to a law enforcement agency except pursuant to a warrant. (Status: The measure did not move from the Assembly Committee on Public Safety.)
SB 482 (Lara, Chapter 708, Statutes of 2016) required a health care provider authorized to prescribe, order, administer, or furnish a controlled substance to consult CURES prior to prescribing a Schedule II, III or IV drug to a patient for the first time and at least once every four months thereafter if the substance remains part of the patient’s treatment. The bill provided exemptions from the responsibility to consult the CURES system, including while a patient is admitted to a certain type of facility, if a patient receives a non-refillable five-day supply or less prescription in conjunction with a surgery, and in the event of a technological failure or inability to access the CURES system.
SB 1258 (DeSaulnier) of 2014 would have made several changes to the ways that controlled substances are prescribed and tracked in the CURES and would have required medical providers to use electronic prescribing systems, would have required additional reporting of controlled substance prescribing, and would have placed additional restrictions on the prescribing of controlled substances.
(Status: The bill was held in the Senate Committee on Appropriations.)
SB 809 (De Saulnier, Chapter 400, Statutes of 2013) established a funding mechanism to update and maintain CURES, required all prescribing health care practitioners to apply to access CURES information, and established processes and procedures for regulating prescribing licensees through CURES and securing private information.
SB 151 (Burton, Chapter 406, Statutes of 2003) made the CURES program permanent.
AB 2655 (Matthews, Chapter 345, Statutes of 2002) extended the CURES program to 2008 and provided access to CURES data by licensed health care providers.
SB 1308 (Committee on Business and Professions, Chapter 655, Statutes of 1999) extended the sunset date on the CURES program to July 1, 2003 and required DOJ to submit annual status reports on the program to the Legislature.
AB 3042 (Takasugi, Chapter 738, Statutes of 1996) established a three year pilot program, beginning in July 1997, for the electronic monitoring of prescribing and
dispensing of Schedule II controlled substances.
- Arguments in Support. The California Police Chiefs Association (Cal Chiefs) writes in support of AB 1751. According to Cal Chiefs, the bill would “empower the role of the Department of Justice in regulating private vendors entrusted with manufacturing prescription pads by adding new controls, limiting the number of approved printers, and linking unique serial numbers to CURES.” Cal Chiefs describes the bill as part of a larger effort to “fight back against the alarming opioid crisis affecting our state and nation.”
The District Attorney of San Diego County, Summer Stephan, supports the bill.
DA Stephan states that the bill “helps to further the administration of justice and promote safety in our community.” The California District Attorneys Association (CDAA) echoes this sentiment on behalf of all 58 county district attorneys. CDAA writes that the bill “would help reduce prescription form forgery and fraud, which will help prevent prescription drug abuse.”
The California Life Sciences Association (CLSA) supports AB 1753, representing the state’s biotechnology, pharmaceutical, medical device and diagnostics companies, venture capital firms, research universities, and nearly 30,000 employees in the industry. CLSA cites specific examples of criminal cases where the legislation would have aided law enforcement investigations: “For instance, in Modesto, a single four-person prescription fraud ring put over 50,000 prescription opioids on the street within a year, using stolen prescription pads and forged prescriptions.” CLSA writes that AB 1753 would be a “positive step towards eliminating illicit sources of prescription opioids.”
NOTE:
Double-referral to Senate Public Safety Committee, second.
SUPPORT AND OPPOSITION:
Support:
America’s Physician Groups
California Association of Health Underwriters
California Chiropractic Association
California District Attorneys Association
California Life Sciences Association
California Police Chiefs Association
California State Board of Pharmacy
Consumer Attorneys of California
County Behavioral Health Directors Association of California
OCHIN
Office of the District Attorney of San Diego County
Troy and Alana Pack Foundation
Opposition: None on file as of June 13, 2018.
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1753
Author:(Low)
As Amended Ver:April 18, 2018
Majority vote
Committee | Votes | Ayes | Noes |
Business & Professions | 15-1 | Low, Brough, Arambula, Baker, Bloom, Chen, Chiu, Eggman, Fong, Gipson, Grayson, Holden, Irwin, Mullin, Ting | Cunningham |
Public Safety | 7-0 | Jones-Sawyer, Lackey, Carrillo, Kamlager-Dove, Kiley, Quirk, Santiago | |
Appropriations | 16-0 | Gonzalez Fletcher, Bigelow, Bloom, Bonta, Calderon, Carrillo, Chau, Eggman, Fong, Friedman, Gallagher, Eduardo Garcia, Nazarian, Obernolte, Quirk, Reyes |
|
SUMMARY: Authorizes the Department of Justice (DOJ) to cap the number of security printers approved to manufacture regulated prescription pads to three and allows DOJ to reduce or limit the number of printers to no fewer than three through regulation; requires that all prescription forms be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the state's prescription drug monitoring program (PDMP), CURES.
FISCAL EFFECT: According to the Assembly Committee on Appropriations, one-time costs of $900,000 to DOJ to implement a web-based portal to collect information about prescription pads and include information in the state's PDMP and ongoing costs in the range of $200,000 annually to DOJ for ongoing information technology support for the new application.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
The opioid crisis ravaging communities throughout our nation and California must first and foremost be addressed through solutions rooted in a public health approach. However, prescription drug abuse and diversion continues to be a pressing public safety issue as well. As instances of addiction to pharmaceutical opioids grows, criminal enterprises derive tremendous profit through prescription pad theft and fraud. Because current statute provides for little effective regulation of dozens of security printers entrusted with manufacturing these pads, it is challenging for law enforcement to track prescriptions that may have been written with counterfeit or stolen pads. AB 1753 will tighten existing controls involved in the security printers program and ensure that prescriptions filled using illicit pads can be linked to prescription data collected through the successful CURES database.
Background.
Security Printers and Prescription Pads. Under the DOJ's Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant's intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
All prescription forms are required to contain a number of security features and identifying markers. However, this does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.
One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.
Allowing the DOJ to cap the number of approved security printers and reduce the number through regulation to three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0003317
Date of Hearing: May 2, 2018
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez Fletcher, Chair
ABPCA Bill Id:AB 1753
Author:(Low) – As Amended Ver:April 18, 2018
Policy Committee: | Business and Professions Public Safety | Vote: Vote: | 15 - 1 7 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill increases oversight and control of prescription pads. Specifically, this bill:
- Authorizes the Department of Justice (DOJ) to reduce or limit the number of printer vendors used to produce prescription pads to no fewer than three vendors, as specified.
- Requires prescription forms for controlled substance prescriptions to have a unique serialized number.
- Requires the information submitted by a drug dispenser to the DOJ to include the serial number for the corresponding prescription pad, if applicable.
- Requires, within the next working day following delivery, a security printer to submit to DOJ via web-based application specified information for all prescription pads delivered.
FISCAL EFFECT:
- One-time costs of $900,000 GF to DOJ to implement a web-based portal to collect information about prescription pads and include information in the state's prescription drug monitoring system, called CURES.
- Ongoing costs in the range of $200,000 GF annually to DOJ for ongoing information technology support for the new application.
COMMENTS:
- Purpose. This bill is intended to prevent diversion of prescription drugs to street use. The author notes as more people have become addicted to pharmaceutical opioids, criminal enterprises have derived tremendous profit through prescription pad theft and fraud. Until electronic prescribing is universal statewide, the author argues, the state should more closely monitor prescription pads to prevent prescription pad theft and fraud.
- Background. Both oversight of prescription pads and prescription drug monitoring programs (PDMPs) are critical to curb prescription drug abuse. Currently, DOJ has approved over 40 security printers that meet DOJ standards for prescription pads. The state PDMP, CURES, allows health professionals, regulators, and law enforcement personnel to conduct web-based searches of prescription drug data in order to inform prescribing and dispensing practices and to aid in investigations. This bill will also include in CURES serial number information that will allow tracking of prescription pads, which should assist in identifying fraud and theft.
- Related Legislation. There is a large number of bills introduced this year addressing various aspects of the opioid epidemic, including improvements to the state's prescription drug monitoring program, requirements for e-prescribing, limits on opioid prescribing, higher reimbursement for drug treatment providers, and improved access to naloxone, which can prevent death from overdose.
- Support and Opposition. This bill is supported by a disparate group of health, public safety, and consumer stakeholders. Health care providers had previously expressed concern about prescription pad availability, but no opposition has been expressed to the current version as recently amended to authorize, instead of require, DOJ to reduce the number of prescription pad vendors.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 24, 2018
Counsel: David Billingsley
ASSEMBLY COMMITTEE ON
Reginald Byron Jones-Sawyer, Sr., Chair
ABPCA Bill Id:
Author:() – As Ver:
SUMMARY: Authorizes the Department of Justice (DOJ) to limit the number of printer vendors used to produce prescription drug forms to no fewer than three vendors, as specified. Requires prescription forms for controlled substance prescriptions to have a unique serialized number. Requires the information submitted by a dispensing pharmacy, clinic, or other dispenser to the DOJ to include the serial number for the corresponding prescription pad, if applicable. Specifically, this bill:
- Authorizes DOJ to limit the number security printers used to produce prescription drug forms to no fewer three printers.
- States that DOJ shall ensure that any reduction of approved security printer vendors does not impact the ability of vendors to meet demand for prescription forms.
- Requires DOJ to establish policies governing the selection of the three approved vendors based on ability to meet demand and prevent fraud and theft of prescription pads and the process of revoking approval for currently authorized printers in excess of three.
- Requires the prescription forms for controlled substances to include a uniquely serialized number, in a manner prescribed by the DOJ.
- States that within the next working day following delivery, a security printer shall submit via Web-based application, as specified by DOJ, all of the following information for all prescription forms delivered:
- Serial numbers of all prescription forms delivered;
- All prescriber names and Drug Enforcement Administration Controlled Substance Registration Certificate numbers displayed on the prescription forms; and
- The delivery shipment recipient names.
- The date of delivery
- Serial numbers of all prescription forms delivered;
- Updates current CURES reporting requirements to include the serial number for a dispensed prescription’s corresponding prescription pad, if applicable.
EXISTING LAW:
- Establishes the California Uniform Controlled Substances Act which regulates controlled substances. (Health & Saf. Code, § 11000 et seq.)
- Defines controlled substances as any drug, precursor, or substance categorized in any of the five schedules based on their danger and potential for abuse. (Health & Saf. Code, §§ 11007; 11054-11058.)
- Defines “prescription” as “an oral order or electronic transmission prescription for a controlled substance given individually for the person(s) for whom prescribed, directly from the prescriber to the furnisher or indirectly by means of a written order of the prescriber.” (Health & Saf. Code, §11027.)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, naturopathic doctor, pharmacist, certified nurse-midwife, nurse practitioner; a pharmacist or registered nurse or physician assistant acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (Health & Saf. Code, § 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (Health & Saf. Code, § 11150.)
- Specifies that a prescription for a controlled substance shall only be issued for a legitimate medical purpose and establishes responsibility for proper prescribing on the prescribing practitioner. States that a violation shall result in imprisonment for up to one year or a fine of up to $20,000, or both. (Health & Saf. Code, § 11153.)
- Requires special prescription forms for controlled substances to be obtained from security printers approved by DOJ, establishes certain criteria for features on the forms and requires controlled substance prescriptions to be made on the specified form. (Health & Saf. Code, §§ 11161.5, 11162.1, 11164.)
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES) for electronic monitoring of Schedule II, III and IV controlled substance prescriptions. The CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the DOJ at the time prescriptions are dispensed. (Health & Saf. Code, § 11165.)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education and research. (Health & Saf. Code, § 11165, subd. (a).)
- Establishes privacy protections for patient data and specifies that CURES data can only be accessed by appropriate state, local and federal persons or public agencies for disciplinary, civil or criminal actions. Specifies that CURES data shall also only be provided, as determined by DOJ, to other agencies or entities for educating practitioners and others, in lieu of disciplinary, civil or criminal actions. Authorizes non-identifying CURES data to be provided to public and private entities for education, research, peer review and statistical analysis. (Health & Saf. Code, § 11165, subd. (c).)
- Provides that pharmacies or clinics, in filling a prescription for a federally Scheduled II, III or IV drug, shall provide weekly information to DOJ including the patient's name, date of birth, the name, form, strength and quantity of the drug, and the pharmacy name, pharmacy number and the prescribing physician information. (Health & Saf. Code, § 11165, subd. (d).)
- Provides that a licensed health care practitioner eligible to prescribe Schedule II, III or IV controlled substances, or a pharmacist, shall apply to participate in the CURES PDMP by January 1, 2016. Authorizes DOJ to deny an application or suspend a subscriber for certain violations and falsifying information. Provides that the history of controlled substances dispensed to a patient based on CURES data that is received by a practitioner or pharmacist shall be considered medical information, subject to provisions of the Confidentiality of Medical Information Act. (Health & Saf. Code, § 11165.1.)
- Authorizes the DOJ to conduct audits of the CURES PDMP system and its users and create a system for issuing citations for violations. (Health & Saf. Code, 1165.2, subd. (a) & (b).)
- Requires a health care practitioner authorized to prescribe, order, administer, or furnish a controlled substance to consult the CURES database to review a patient’s controlled substance history, as specified.
- Requires health practitioners who prescribe or administer a controlled substance classified in Schedule II to make a record containing the name and address of the patient, date, and the character, name, strength, and quantity of the controlled substance prescribed, as well as the pathology and purpose for which the controlled substance was administered or prescribed. (Health & Saf. Code, § 11190, subd. (a) and (b).)
- Requires prescribers who are authorized to dispense Schedule II, III or IV controlled substance in their office or place of practice to record and maintain information for three years for each such prescription that includes the patient's name, address, gender, and date of birth, prescriber's license and license number, federal controlled substance registration number, state medical license number, National Drug Code number of the controlled substance dispensed, quantity dispensed, diagnosis code, if available, and original date of dispensing. Requires that this information be provided to DOJ on a monthly basis. (Health & Saf. Code, § 11190, subd. (c).)
FISCAL EFFECT:
Unknown
COMMENTS:
- Author's Statement: According to the author, "The opioid crisis ravaging communities throughout our nation and the State of California must first and foremost be addressed through solutions rooted in a public health approach. However, prescription drug abuse and diversion continues to be a pressing public safety issue as well. As instances of addiction to pharmaceutical opioids grows, criminal enterprises derive tremendous profit through prescription pad theft and fraud. Because current statute provides for little effective regulation of dozens of security printers entrusted with manufacturing these pads, it is challenging for law enforcement to track prescriptions that may have been written with counterfeit or stolen pads. AB 1753 will tighten existing controls involved in the security printers program and ensure that prescriptions filled using illicit pads can be linked to prescription data collected through the successful CURES database.”
- DOJ Regulation of Drug Prescriptions: Under the DOJ’s Triplicate Prescription Program (TPP), first launched in 1939 under Attorney General Earl Warren, health practitioners were required to use serialized triplicate prescription forms when prescribing a Schedule II controlled substance. One copy was provided to the patient; another was retained for the prescriber’s records. The third copy of each triplicated prescription was sent to the Bureau of Narcotics Enforcement within the DOJ’s Division of Law Enforcement, which used the records to investigate potential fraud or criminal diversion of controlled substances. When the TPP was replaced by the CURES database in 2005, the triplicate prescription form requirement for Schedule II drugs was replaced with a new requirement that these prescriptions be issued on a special form obtained from an approved printer.
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Statute’s required features of prescription pads for controlled substances are relatively straightforward. All prescription forms must contain the following:
- A latent, repetitive “void” pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word “void” shall appear in a pattern across the entire front of the prescription;
- A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words “California Security Prescription;”
- A chemical void protection that prevents alteration by chemical washing;
- A feature printed in thermochromic ink;
- An area of opaque writing so that the writing disappears if the prescription is lightened;
- A description of the security features included on each prescription form;
- Six quantity check off boxes printed on the form so that the prescriber may indicate the quantity, consisting of ranges of 25, and a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form;
- A statement printed on the bottom of the prescription blank that the “Prescription is void if the number of drugs prescribed is not noted;”
- The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner;
- Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered’
- The date of origin of the prescription;
- A check box indicating the prescriber’s order not to substitute;
- An identifying number assigned to the approved security printer by the DOJ; and,
- A check box by the name of each prescriber when a prescription form lists multiple prescribers; each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
- A latent, repetitive “void” pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word “void” shall appear in a pattern across the entire front of the prescription;
This list of requirements does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.
Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.
This bill would allow DOJ to limit the number of approved security printers to three.
- CURES Integration and Opioid Abuse: According to recent reports regarding America’s opioid epidemic, almost 2 million Americans abused or were dependent on prescription opioids in 2014. In 2015, more than 15,000 people died from overdoses involving prescription opioids. Today, nearly half of all U.S. opioid overdose deaths involve a prescription opioid and, due to the large population that abuses prescription opioids, over 1,000 people are treated in emergency departments for misusing prescription opioids every day. <https://www.cdc.gov/drugoverdose/opioids/prescribed.html> (as of April 14, 2017.)
In order to address the prevalence of prescribed opioid abuses, the DOJ implemented and maintains the CURES PDMP searchable database so that practitioners have increased access to information regarding a patient’s prescription history. However, because current law does not provide authority for the CURES PDMP to integrate with health information technology systems, health care practitioners face several additional burdens including, but not limited to, a delay in access to potentially vital information for rapid treatment, increased opportunities for patients to abuse practitioner services, and decreased peer-to-peer benefits between health information technology providers. During the process of decommissioning the original CURES database and transitioning to CURES 2.0, the current operating system, the DOJ expressed the need to address these concerns through integration. <https://www.cdph.ca.gov/programs/cclho/Documents/SMALL%2020140203%20PDMP%20A%20Powerful%20Tool.pdf> (as of April 14, 2017.) - Argument in Support: According to the Consumer Attorneys of California, “Prescription pads are currently not required to be uniquely serialized, which means that prescription data in CURES cannot always be traced back to a specific written prescription. AB 1753 would allow the California Department of Justice to limit the number of Security Printers to 3 and require standard serialization across pad manufacturers. This would allow law enforcement to trace criminal diversion of these pads, and ultimately prevent illegitimate prescriptions of dangerous drugs like opioids.”
- Argument in Opposition: According to the California Medical Association, “This bill allows the California Department of Justice (DOJ) to pick three security prescription pad vendors from amongst the numerous qualified and approved vendors who are currently printing these security prescription pads, and allow only those three to keep their status as an approved vendor. While we support your intent of reducing fraud and diversion of these prescription pads, removing the majority of currently approved vendors from the program with no cause and to such a limited number raises concerns around resources and cost.
“Prescribers are required to use secure prescription pads when prescribing controlled substances, and these pads must be obtained from vendors approved by the DOJ who meet specific requirements set out by the Department. Despite security measures, prescription pads are still stolen and produced fraudulently. CMA supports efforts to reduce fraud and diversion, but those efforts must not unfairly penalize vendors who have not violated any rules, nor been out of compliance with DOJ requirements simply because the Department has authorized more vendors than they are able to appropriately monitor.
“Most concerning, though, is the availability of these secure prescription pads and their cost should this bill pass. A vendor attestation done by speculation of future ability to provide the volume of prescription pads needed, in the same timeframe and at the same cost as when hundreds more were fulfilling the same duties, is unreliable at best. Some method of expelling bad actors from the participating vendors, or a more efficient means of tracking these prescription pads must be utilized to combat fraud and diversion, instead of arbitrarily cutting hundreds of vendors and keeping the Department’s preferential three.” - Related Legislation:
- AB 1752 (Low), would add Schedule V controlled substances to the CURES database. AB 1752 is awaiting hearing in the Assembly Public Safety Committee.
- AB 2086 (Gallagher) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber. AB 2086 is pending a hearing in the Assembly Appropriations Committee.
- AB 2487 (McCarty) would add opioid addiction training as a continuing medical education requirement for certain physicians to increase the availability of buprenorphine treatment. AB 2487 is pending a hearing in the Assembly Appropriations Committee.
- AB 2741 (Burke) would limit all opioid prescriptions for minors to a maximum of five days, with exceptions, and require a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain written consent prior to writing the prescription. AB 2741 is pending a hearing in the Assembly Appropriations Committee.
- Prior Legislation:
- AB 40 (Santiago), Chapter607, Statutes of 2017, requires DOJ to make electronic prescription drug records contained in its Controlled Substance Utilization Review and Evaluation System (CURES) accessible through integration with a health information technology system no later than October 1, 2018, if that system meets certain information security and patient privacy requirements.
- SB 482 (Lara), Chapter 708, Statutes of 2016, required prescribers to consult the CURES prior to prescribing a Schedule II or III drug to a patient for the first time and required a dispenser to consult the CURES system prior to dispensing a Schedule II or III drug to a patient for the first time.
- AB 679 (Allen), Chapter 778, Statutes of 2015, extended the date by which specified health care practitioners and pharmacists must register with the CURES Prescription Drug Monitoring Program (PDMP) by six months, from January 1, 2016 to July 1, 2016.
- SB 809 (De Saulnier), Chapter 400, Statutes of 2013, made various changes to the funding and operations of the CURES PDMP, including the requirement that practitioners who prescribe Schedule II, III and IV controlled substances and pharmacists also enroll in and consult the CURES PDMP.
- SB 360 (De Saulnier), Chapter 418, Statutes of 2011, updated CURES to reflect the new PDMP, authorized DOJ to initiate administrative enforcement actions to prevent the misuse of confidential information collected through CURES, and specified that what constitutes a Schedule II, III, or IV controlled substance for purposes of reporting in CURES shall be determined according to federal rather than California schedules.
- AB 40 (Santiago), Chapter607, Statutes of 2017, requires DOJ to make electronic prescription drug records contained in its Controlled Substance Utilization Review and Evaluation System (CURES) accessible through integration with a health information technology system no later than October 1, 2018, if that system meets certain information security and patient privacy requirements.
REGISTERED SUPPORT / OPPOSITION:
Support
California Association of Health Underwriters
California District Attorneys Association
California Life Sciences Association
California Police Chiefs
Consumer Attorneys of California
OCHIN
San Diego County, Office of the District Attorney
Troy and Alana Pack Foundation
Opposition
None
Analysis Prepared by:
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 1753
Author:(Low) – As Introduced Ver:January 3, 2018
SUBJECT: Controlled substances: CURES database.
SUMMARY: Beginning January 1, 2020, limits the number of security printers approved by the California Department of Justice (DOJ) to manufacture regulated prescription pads to three; requires that all prescription be uniquely serialized; and requires that the DOJ link prescription pad serial numbers to corresponding records in the state’s prescription drug monitoring program (PDMP) when available.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) § 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC § 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC § 11156)
- Requires that all prescription forms for controlled substance prescriptions be obtained from security printers approved by the DOJ and sets a number of parameters for the DOJ’s approval process. (HSC § 11161.5)
- Provides that when a prescriber’s authority to prescribe controlled substances is restricted, the law enforcement agency or licensing board that sought the restrictions shall provide the prescriber’s name, category of licensure, license number, and the nature of the restrictions imposed on the prescriber to security printers, the DOJ, and the Board of Pharmacy. (HSC § 11161.7)
- Lists a number of required features that must be included for all prescription forms for controlled substances, including fraud-prevention identifiers, printing information, and information relating to the prescribing practitioner. (HSC § 11162.1)
- Criminalizes the counterfeiting of prescription pads and the possession of counterfeit prescription pads. (HSC §§ 11162.5-11162.6)
- Requires all prescriptions and dispensations of controlled substances to meet a series of requirements including use of a controlled substance prescription form, presence of a signature and date in ink, and the address of the patient. (HSC § 11164)
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES), a PDMP maintained by the DOJ for the purposes of collecting records of dispensed controlled substances for review by licensed prescribers and dispensers, regulatory investigators, law enforcement, and statistical researchers. (HSC § 11165(a))
- Requires pharmacists and other dispensers to report information to CURES within 7 days relating to prescriptions of Schedule II, III, and IV controlled substances. (HSC § 11165(d))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Provides dedicated funding for the CURES program through an annual license fee of $6 assessed for licensees authorized to prescribe or dispense controlled substances in California. (Business and Professions Code (BPC) § 208)
- Authorizes the DOJ to seek voluntarily contributed private funds from insurers, health care service plans, qualified manufacturers, and other donors for the purpose of supporting CURES. (HSC § 11165.5)
- Allows the DOJ to conduct audits of CURES and its users and issue citations and fines for system misuse. (HSC § 11165.2)
- Requires the CURES database to comply with all applicable federal and state privacy and security laws and regulations and requires the DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165(c))
THIS BILL:
- Finds and declares that the prevailing use of paper prescription pads to prescribe controlled substances leads to significant instances of theft and fraud each year; that electronic prescribing is the most effective way to combat prescription pad theft and fraud; and that tighter restrictions on prescription pads is needed for prescriptions not made electronically.
- Requires the DOJ, beginning January 1, 2020, to limit the number of approved security printers to three.
- Requires the DOJ to establish policies governing the selection of the three approved vendors based on ability to meet demand and prevent fraud and theft of prescription pads and the process of revoking approval for currently authorized printers in excess of three.
- Updates current CURES reporting requirements to include the serial number for a dispensed prescription’s corresponding prescription pad, if applicable.
FISCAL EFFECT: Unknown; this bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
The opioid crisis ravaging communities throughout our nation and the State of California must first and foremost be addressed through solutions rooted in a public health approach. However, prescription drug abuse and diversion continues to be a pressing public safety issue as well. As instances of addiction to pharmaceutical opioids grows, criminal enterprises derive tremendous profit through prescription pad theft and fraud. Because current statute provides for little effective regulation of dozens of security printers entrusted with manufacturing these pads, it is challenging for law enforcement to track prescriptions that may have been written with counterfeit or stolen pads. AB 1753 will tighten existing controls involved in the security printers program and ensure that prescriptions filled using illicit pads can be linked to prescription data collected through the successful CURES database.
Background.
Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a necessarily critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
Security Printers and Prescription Pads. Written prescriptions have been regulated in the State of California since 1929, when a statute was first enacted to require that certain drugs be dispensed only with a written prescription from a licensed physician, dentist, or veterinarian. These prescriptions were required to include the name and address of the individual receiving the drug, and for three years all prescription records were required to remain “open to inspection by the prescriber and properly authorized officers of the law, including all inspectors of the division of narcotic enforcement and of the state board of pharmacy.” This requirement was later expanded to include all prescription drugs.
Under the DOJ’s Triplicate Prescription Program (TPP), first launched in 1939 under Attorney General Earl Warren, health practitioners were required to use serialized triplicate prescription forms when prescribing a Schedule II controlled substance. One copy was provided to the patient; another was retained for the prescriber’s records. The third copy of each triplicated prescription was sent to the Bureau of Narcotics Enforcement within the DOJ’s Division of Law Enforcement, which used the records to investigate potential fraud or criminal diversion of controlled substances. When the TPP was replaced by the CURES database in 2005, the triplicate prescription form requirement for Schedule II drugs was replaced with a new requirement that these prescriptions be issued on a special form obtained from an approved printer.
Under the DOJ’s Security Prescription Printers Program, all paper prescriptions of any Schedule II through V controlled substance must use special tamper-resistant forms obtained from manufacturers approved by the DOJ. Vendors wishing to operate as approved security printers submit an application to the DOJ and are initially required to provide an applicant’s name, address, and telephone number along with a description of the applicant’s intended policies and procedures for ensuring that prescription pads are delivered only to valid prescribers. The DOJ then generally screens the applicant and any other individuals affiliated with the applicant’s business for any disqualifying criminal history records. Once approved, printers are required to retain records for inspection by the DOJ and may have be fined or have their approval revoked for misconduct.
Statute’s required features of prescription pads for controlled substances are relatively straightforward. All prescription forms must contain the following:
- A latent, repetitive “void” pattern shall be printed across the entire front of the prescription blank; if a prescription is scanned or photocopied, the word “void” shall appear in a pattern across the entire front of the prescription.
- A watermark shall be printed on the backside of the prescription blank; the watermark shall consist of the words “California Security Prescription.”
- A chemical void protection that prevents alteration by chemical washing.
- A feature printed in thermochromic ink.
- An area of opaque writing so that the writing disappears if the prescription is lightened.
- A description of the security features included on each prescription form.
- Six quantity check off boxes printed on the form so that the prescriber may indicate the quantity, consisting of ranges of 25, and a space shall be provided to designate the units referenced in the quantity boxes when the drug is not in tablet or capsule form.
- A statement printed on the bottom of the prescription blank that the “Prescription is void if the number of drugs prescribed is not noted.”
- The preprinted name, category of licensure, license number, federal controlled substance registration number, and address of the prescribing practitioner.
- Check boxes shall be printed on the form so that the prescriber may indicate the number of refills ordered.
- The date of origin of the prescription.
- A check box indicating the prescriber’s order not to substitute.
- An identifying number assigned to the approved security printer by the DOJ.
- A check box by the name of each prescriber when a prescription form lists multiple prescribers; each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by his or her name.
This list of requirements does not include a uniquely serialized number, and delivery information reported by security printers to the DOJ does not include information specifically identifying prescription pads through a serial number. This means that when prescription pads are lost or stolen, there is no way for the DOJ or law enforcement to effectively identify the circulation of prescriptions written on those pads. There is also no realistic method of linking a particular pad to dispensed prescriptions, even though the state tracks all Schedule II-IV drug prescriptions dispensed in California through CURES.
One of the stated challenges to requiring standardized serialization of prescription pads is that the number of approved security printers that are each individually manufacturing pads throughout the state without significant restriction or coordination. Approximately 43 security printers are currently approved by the DOJ and operating throughout the state. The DOJ has stated that it believes this to be too many printers to substantially standardize the production of forms in a way that would allow for unique identifiers to be consistently applied in a way that can be tracked through CURES or any other system.
Allowing the DOJ to limit the number of approved security printers to three will provide for a more manageable amount of coordination between manufacturers. This will allow for prescription pads to be tracked by law enforcement when lost or stolen, and for serialized pads to be linked to CURES. The tighter regulation could also arguably make it easier for law enforcement to identify counterfeit or fraudulent prescription pads sold on the street.
Current Related Legislation. AB 1751 (Low) would provide a framework for the CURES PDMP to connect with other states that comply with California’s patient privacy and data security standards.
AB 1752 (Low) would add Schedule V drugs to the CURES database and change the requirement for pharmacists to report dispensed prescriptions from seven days to the following business day.
AB 2384 (Arambula) would remove barriers to medication-assisted treatment, such as prior authorization requirements and limits on coverage.
AB 2741 (Burke) would limit all opioid prescriptions for minors to a maximum of 5 days, with exceptions, and require a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain written consent prior to writing the prescription.
AB 2859 (Caballero) would increase safe storage practices among parents to prevent access to prescription drugs in the home by children and adolescents.
AB 2086 (Gallagher) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber.
AB 2487 (McCarty) would add opioid addiction training as a continuing medical education requirement for certain physicians to increase the availability of buprenorphine treatment.
AB 2486 (McCarty) would establish the Opioid Prevention and Rehabilitation Program Fund to treat opioid addiction by providing existing programs the additional funding.
AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance schedules.
AB 1963 (Waldron) would incentivize medical providers to become certified prescribers of medication-assisted treatment by increasing the reimbursement rates for providers who prescribe these drug treatments.
AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions.
AB 2760 (Wood) would require certain prescriptions for opioids to also include a co-prescription for naloxone.
Prior Related Legislation. AB 3042 (Takasugi, Chapter 345, Statutes of 2002) first established CURES as a pilot project operating concurrently with the state’s Triplicate Prescription Program.
SB 151 (Burton, Chapter 406, Statutes of 2003) made CURES the state’s permanent prescription tracking program and added Schedule III drugs to the database.
SB 734 (Torlakson, Chapter 487, Statutes of 2005) created the framework to upgrade the CURES prescription database into a searchable, client-facing PDMP and gave the DOJ exclusive duties for approving applications by vendors to become security printers authorized to manufacture prescription pads eligible for controlled substance prescriptions.
SB 360 (DeSaulnier, Chapter 418, Statutes of 2011) authorized the DOJ to impose administrative fines for misuse of CURES and for malfeasance in security printers’ manufacturing of prescription pads.
SB 809 (DeSaulnier, Chapter 400, Statutes of 2013) established new healing arts license fees to fund the development and maintenance a new and improved “CURES 2.0” database.
AB 40 (Santiago, Chapter 607, Statutes of 2017) required the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
ARGUMENTS IN SUPPORT:
California Police Chiefs Association (Cal Chiefs) writes in support of AB 1751. According to Cal Chiefs, the bill would “empower the role of the Department of Justice in regulating private vendors entrusted with manufacturing prescription pads by adding new controls, limiting the number of approved printers, and linking unique serial numbers to CURES.” Cal Chiefs describes the bill as part of a larger effort to “fight back against the alarming opioid crisis affecting our state and nation.”
The District Attorney of San Diego County, Summer Stephan, supports the bill. DA Stephan states that the bill “helps to further the administration of justice and promote safety in our community.” The California District Attorneys Association (CDAA) echoes this sentiment on behalf of all 58 county district attorneys. CDAA writes that the bill “would help reduce prescription form forgery and fraud, which will help prevent prescription drug abuse.”
The California Life Sciences Association (CLSA) supports AB 1753, representing the state’s biotechnology, pharmaceutical, medical device and diagnostics companies, venture capital firms, research universities, and nearly 30,000 employees in the industry. CLSA cites specific examples of criminal cases where the legislation would have aided law enforcement investigations: “For instance, in Modesto, a single four-person prescription fraud ring put over 50,000 prescription opioids on the street within a year, using stolen prescription pads and forged prescriptions.” CLSA writes that AB 1753 would be a “positive step towards eliminating illicit sources of prescription opioids.”
ARGUMENTS IN OPPOSITION:
The California Medical Association (CMA) has taken an “oppose unless amended” position on AB 1753. CMA writes that it supports the intent of reducing fraud and diversion of prescription pads, but expresses concerns about “removing the majority of currently approved vendor.” CMA specifically cites concerns regarding “the availability of these secure prescription pads and their cost should this bill pass.” The California Dental Association (CDA) takes a similar “oppose unless amended” position, referring to the reduction in the number of approved printers as effectively being a “state-induced monopoly.” Both organizations request that alternative methods of restricting prescription pad manufacturing be enacted rather than limiting the number of approved printers.
REGISTERED SUPPORT:
America’s Physician Groups
California Association of Health Underwriters
California Chiropractic Association
California District Attorneys Association
California Life Sciences Association
California Police Chiefs Association
California State Board of Pharmacy
Consumer Attorneys of California
OCHIN
San Diego County District Attorney Summer Stephan
Troy and Alana Pack Foundation
REGISTERED OPPOSITION:
California Dental Association
California Medical Association
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Business, Professions and Economic Development
Assembly Floor
Assembly Standing Committee on Public Safety
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):